Literature DB >> 1714871

Export of intracellular HBsAg in chronic hepatitis B virus infection is related to viral replication.

J Y Lau1, V G Bain, S E Davies, G J Alexander, R Williams.   

Abstract

Serum and liver HBsAg bear an inverse relation to each other during the evolution of chronic hepatitis B virus infection and the quantity of HBsAg in tissue rises gradually with time. In this study, intracellular and extracellular levels of HBsAg were measured by radioimmunoassay in primary culture of hepatocytes from 30 patients with chronic hepatitis B virus infection to determine a possible relationship with hepatitis B virus replication. Serum levels of HBsAg correlated with markers of active viral replication (serum hepatitis B virus DNA, p less than 0.005, and tissue HBcAg, p less than 0.02) but inversely with tissue HBsAg (p less than 0.05). In similar fashion, in vitro export of HBsAg was also related to the presence of active viral replication markers (serum hepatitis B virus DNA, p less than 0.02, and tissue HBcAg, p less than 0.05) and negatively with tissue HBsAg (p less than 0.001). Export of HBeAg also correlated positively with markers of active viral replication (serum hepatitis B virus DNA, p less than 0.05 and tissue HBcAg, p less than 0.05). Further experiments indicated that intrahepatic pre-S1 and pre-S2 correlated closely with intrahepatic HBsAg, indicating that a failure to export HBsAg was unlikely to be attributable to deficient intracellular expression of pre-S1 or pre-S2. These data indicate that in vitro primary hepatocyte culture of hepatitis B virus-infected cells provides an accurate reflection of in vivo export of HBsAg and that this is closely related to the presence of active viral replication.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1714871

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  8 in total

1.  Differential effect of chronic hepatitis D virus infection on intrahepatic expression of hepatitis B viral antigen.

Authors:  J Y Lau; B C Portmann; G J Alexander; R Williams
Journal:  J Clin Pathol       Date:  1992-04       Impact factor: 3.411

2.  In situ analysis of intrahepatic virological events in chronic hepatitis B virus infection.

Authors:  Xiaonan Zhang; Wei Lu; Ye Zheng; Weixia Wang; Lu Bai; Liang Chen; Yanling Feng; Zhanqing Zhang; Zhenghong Yuan
Journal:  J Clin Invest       Date:  2016-02-22       Impact factor: 14.808

Review 3.  From HCV To HBV Cure.

Authors:  Raymond F Schinazi; Tarik Asselah
Journal:  Liver Int       Date:  2017-01       Impact factor: 5.828

4.  Hepatic HLA antigen display in chronic hepatitis B virus infection. Relation to hepatic expression of HBV genome/gene products and liver histology.

Authors:  J Y Lau; G L Bird; N V Naoumov; R Williams
Journal:  Dig Dis Sci       Date:  1993-05       Impact factor: 3.199

5.  Hepatic expression of interferon-alpha in chronic hepatitis B virus infection.

Authors:  J W Fang; P C Wu; C L Lai; C K Lo; A Meager; J Y Lau
Journal:  Dig Dis Sci       Date:  1994-09       Impact factor: 3.199

6.  Antibody-directed complement-mediated cytotoxicity to hepatocytes from patients with chronic hepatitis B.

Authors:  T I Michalak; J Y Lau; B M McFarlane; G J Alexander; A L Eddleston; R Williams
Journal:  Clin Exp Immunol       Date:  1995-05       Impact factor: 4.330

7.  Hepatitis B Surface Antigen Quantification across Different Phases of Chronic Hepatitis B Virus Infection Using an Immunoradiometric Assay.

Authors:  Kwang Hyun Chung; Won Kim; Byeong Gwan Kim; Ho-Young Lee; Eunhyo Jin; Yuri Cho; Ji Yeon Seo; Hwi Young Kim; Yong Jin Jung; Ji Won Kim; Ji Bong Jeong; Kook Lae Lee
Journal:  Gut Liver       Date:  2015-09-23       Impact factor: 4.519

8.  Pathological impact of hepatitis B virus surface proteins on the liver is associated with the host genetic background.

Authors:  Yuri Churin; Martin Roderfeld; Johannes Stiefel; Tilman Würger; Dirk Schröder; Tomomitsu Matono; Hans-Joachim Mollenkopf; Roberta Montalbano; Malvika Pompaiah; Kurt Reifenberg; Daniel Zahner; Matthias Ocker; Wolfram Gerlich; Dieter Glebe; Elke Roeb
Journal:  PLoS One       Date:  2014-03-04       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.